The Case for Complement and Inflammation in AMD: Open Questions

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 703)


The complement cascade has been identified as a key factor in the pathogenesis of age-related macular degeneration (AMD). As a result, pharmacological modulation of the complement cascade is being investigated as a therapeutic strategy for AMD. The genetic data point to a triggering of the complement cascade, which subsequently cannot be damped down. Despite promising genetic, preclinical and immunolabeling data, important questions remain to be answered regarding the role of complement in the pathogenesis of AMD. The involvement of the complement cascade in the vision threatening stages of AMD, e.g. geographic atrophy and choroidal neovascularization, remain unknown. Additionally, the optimal component(s) of the complement cascade to be targeted for modulation still need to be identified. Answering these and other questions will provide investigators with a clear framework with which to evaluate progress in the field and help guide the development of future clinical therapeutics.


Paroxysmal Nocturnal Hemoglobinuria Choroidal Neovascularization Complement Cascade Geographic Atrophy Corneal Neovascularization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134(3):411–431PubMedCrossRefGoogle Scholar
  2. Bressler NM, Bressler SB, Congdon NG et al (2003) Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121(11):1621–1624PubMedCrossRefGoogle Scholar
  3. Coffey PJ, Gias C, McDermott CJ et al (2007) Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A 104(42):16651–16656PubMedCrossRefGoogle Scholar
  4. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308(5720):421–424PubMedCrossRefGoogle Scholar
  5. Friedman DS, O’Colmain BJ, Munoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564–572PubMedCrossRefGoogle Scholar
  6. Giese MJ, Mondino BJ, Glasgow BJ et al (1994) Complement system and host defense against staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci 35(3):1026–1032PubMedGoogle Scholar
  7. Grossniklaus HE, Cingle KA, Yoon YD, Ketkar N, L’Hernault N, Brown S (2000) Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch Ophthalmol 118(5):625–629PubMedCrossRefGoogle Scholar
  8. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20(6):705–732PubMedCrossRefGoogle Scholar
  9. Hageman GS, Anderson DH, Johnson LV et al (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102(20):7227–7232PubMedCrossRefGoogle Scholar
  10. Haines JL, Hauser MA, Schmidt S et al (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720):419–421PubMedCrossRefGoogle Scholar
  11. Klein RJ, Zeiss C, Chew EY et al (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385–389PubMedCrossRefGoogle Scholar
  12. Klein ML, Ferris FL 3rd, Armstrong J et al (2008) Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115(6):1026–1031PubMedCrossRefGoogle Scholar
  13. Nozaki M, Raisler BJ, Sakurai E et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 103(7):2328–2333PubMedCrossRefGoogle Scholar
  14. Parker CJ (2008) Paroxysmal nocturnal hemoglobinuria: an historical overview. Hematology Am Soc Hematol Educ Program Hematology 1:93–103CrossRefGoogle Scholar
  15. Penfold PL, Killingsworth MC, Sarks SH (1986) Senile macular degeneration. The involvement of giant cells in atrophy of the retinal pigment epithelium. Invest Ophthalmol Vis Sci 27(3):364–371PubMedGoogle Scholar
  16. Rovner BW, Casten RJ (2002) Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry 10(3):305–310PubMedGoogle Scholar
  17. Schnatbaum K, Locardi E, Scharn D et al (2006) Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett 16(19):5088–5092PubMedCrossRefGoogle Scholar
  18. Scholl HP, Fleckenstein M, Fritsche LG et al (2009) CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 4(10):e7418PubMedCrossRefGoogle Scholar
  19. Zhou J, Jang YP, Kim SR, Sparrow JR (2006) Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A 103(44):16182–16187PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual SciencesUniversity of Illinois at ChicagoIllinoisUSA

Personalised recommendations